11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Generation of human bispecific common light chain antibodies by combining animal immunization and yeast display.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Bispecific antibodies (bsAbs) pave the way for novel therapeutic modes of action along with potential benefits in several clinical applications. However, their generation remains challenging due to the necessity of correct pairings of two different heavy and light chains and related manufacturability issues. We describe a generic approach for the generation of fully human IgG-like bsAbs. For this, heavy chain repertoires from immunized transgenic rats were combined with either a randomly chosen common light chain or a light chain of an existing therapeutic antibody and screened for binders against tumor-related targets CEACAM5 and CEACAM6 by yeast surface display. bsAbs with subnanomolar affinities were identified, wherein each separate binding arm mediated specific binding to the respective antigen. Altogether, the described strategy represents a combination of in vivo immunization with an in vitro selection method, which allows for the integration of existing therapeutic antibodies into a bispecific format.

          Related collections

          Author and article information

          Journal
          Protein Eng. Des. Sel.
          Protein engineering, design & selection : PEDS
          Oxford University Press (OUP)
          1741-0134
          1741-0126
          April 01 2017
          : 30
          : 4
          Affiliations
          [1 ] Institute for Organic Chemistry and Biochemistry, Technische Universität Darmstadt, Alarich-Weiss-Strasse 4, D-64287 Darmstadt, Germany.
          [2 ] Protein Engineering and Antibody Technologies, Merck KGaA, Frankfurter Strasse 250, D-64293 Darmstadt, Germany.
          Article
          gzw077
          10.1093/protein/gzw077
          28062646
          e8034368-af21-40bd-85a0-b654b2d0b3ca
          History

          antibody,common light chain,high-throughput screening,yeast surface display,bispecific antibody

          Comments

          Comment on this article